Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 252

Sort by

Sort Order Select

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat steroid-refractory acute graft-versus-host disease

Paul J. Martin

Blood (2020) 135 (19): 1630–1638.

https://doi.org/10.1182/blood.2019000960

Published: 2020

Includes: Supplemental data

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient

Blood (2019) 134 (Supplement_1): 1944.

https://doi.org/10.1182/blood-2019-125276

Published: 2019

Journal Articles

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Haitham Abdelhakim, MD, Luis M. Cortez, BS, Meizhang Li, PhD, Mitchell Braun, BS, Barry S. Skikne, MD, Tara L. Lin, MD, Neil Dunavin, MD, Andrew K Godwin, PhD

Blood (2019) 134 (Supplement_1): 3605.

https://doi.org/10.1182/blood-2019-129455

Published: 2019

Journal Articles

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Emma M. Groarke, MD, Bhavisha A Patel, MD, Carrie Diamond, MD, Fernanda Gutierrez-Rodrigues, PhD, Alana Vicente, MD, Olga Rios, RN, Jennifer Lotter, PA-C, Daniela Baldoni, Ruba Shalhoub, Colin Wu, PhD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 454.

https://doi.org/10.1182/blood-2019-124811

Published: 2019

Journal Articles

Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial

Cornelis N. De Jong, MD, Ellen Meijer, MD PhD, Katerina Bakunina, Erfan Nur, MD PhD, Marinus van Marwijk Kooij, MD PhD, Marco De Groot, MD PhD, Michel Van Gelder, MD PhD, Johan A. Maertens, MD PhD, Jurgen H.E. Kuball, MD PhD, Dries Deeren, MD PhD, Bronno Van Der Holt, PhD, Jan J Cornelissen, MD PhD, Annoek E.C. Broers, MD PhD

Blood (2019) 134 (Supplement_1): 371.

https://doi.org/10.1182/blood-2019-130872

Published: 2019

Journal Articles

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

William Pearse, MD, Barbara Pro, MD, Leo I. Gordon, MD, Reem Karmali, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Amir Behdad, MD, Andreas Klein, MD, Adam M. Petrich, MD, Borko Jovanovic, PhD, Sonali M. Smith, MD, Andrew G Evans, MD PhD

Blood (2019) 134 (Supplement_1): 351.

https://doi.org/10.1182/blood-2019-127390

Published: 2019

Journal Articles

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Dennis Cooper, MD, Jackie Manago, RN, BSN, Vimal Patel, MD, Dale Schaar, MD PhD, Tracy Krimmel, AOCN, APRN-BC, Mary Kate McGrath, RN, APN, Anne Tyno, RN, MSN, APN-C, Roger Strair, MD PhD

Blood (2019) 134 (Supplement_1): 4485.

https://doi.org/10.1182/blood-2019-130598

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

The Immunomodulatory Effect of Triptolide on Mesenchymal Stem Cells in Vitro

Haiping He, MD PhD, Atsuko Takahashi, MT., Yuki Yamamoto, MT, Akiko Hori, Yuta Miharu, MT, Kazuaki Yokoyama, MD PhD, Miwako Narita, MD PhD, Fumitaka Nagamura, MD PhD, Arinobu Tojo, MD PhD, Tonghua Yang, MD PhD, Tokiko Nagamura-Inoue, MD PhD

Blood (2019) 134 (Supplement_1): 5011.

https://doi.org/10.1182/blood-2019-125046

Published: 2019

Journal Articles

Role of Circulating Myeloid-Derived Suppressor Cell (MDSC) in Hodgkin Lymphoma (HL) Patients: Prospective Study

Olga Novosad, PhD MD, Oleksandr Gorbach, PhD, Oksana Skachkova, PhD, Ian Pastushenko, MD, Kateryna Ulianchenko, MD, Nataliia Khranovska, PhD, Tetiana Skrypets, MD, Irina Kryachok, Professor

Blood (2019) 134 (Supplement_1): 5232.

https://doi.org/10.1182/blood-2019-130852

Published: 2019

Journal Articles

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

Blood (2019) 134 (Supplement_1): 5288.

https://doi.org/10.1182/blood-2019-126434

Published: 2019

Journal Articles

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

Max Yano, Jennie Rachel Lance, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4302.

https://doi.org/10.1182/blood-2019-127620

Published: 2019

Journal Articles

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Jennie Rachel Lance, Max Yano, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4303.

https://doi.org/10.1182/blood-2019-131034

Published: 2019

Journal Articles

Galectin-9 from Bone Marrow Mesenchymal Stromal Cells Mediates Immunosuppression on Chimeric Antigen Receptor T Cells

Xinyi Teng, BS, Hao Zhang, MD, Zuyu Liang, MD, Mi Shao, MD, Xiujian Wang, MD, Lijuan Ding, MD, Jiazhen Cui, msc, Yongxian Hu, MD, He Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5609.

https://doi.org/10.1182/blood-2019-131680

Published: 2019

Journal Articles

Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies

Andrea Garofalo, BS, BA, Joseph G Schroers-Martin, MD, Joanne Soo, MD, David M. Kurtz, MD PhD, Brian Sworder, MD PhD, Chih Long Liu, PhD, Benjamin A Pinsky, MD PhD, Helen Luikart, RN, MSN, Ranjana H Advani, MD, Yasodha Natkunam, MD PhD, Kiran Khush, MD, Maximilian Diehn, MD PhD, Arash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 885.

https://doi.org/10.1182/blood-2019-131602

Published: 2019

Journal Articles

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Amy E. DeZern, MD, Marianna Zahurak, MS, Javier Bolanos-Meade, MD, Richard J. Jones, MD

Blood (2019) 134 (Supplement_1): 3320.

https://doi.org/10.1182/blood-2019-122762

Published: 2019

Journal Articles

PTCY keeps on giving!

Vedran Radojcic, Leo Luznik

Blood (2019) 134 (11): 848–849.

https://doi.org/10.1182/blood.2019002284

Published: 2019

NARROW

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

How I treat steroid-refractory acute graft-versus-host disease

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

The Immunomodulatory Effect of Triptolide on Mesenchymal Stem Cells in Vitro

Role of Circulating Myeloid-Derived Suppressor Cell (MDSC) in Hodgkin Lymphoma (HL) Patients: Prospective Study

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Galectin-9 from Bone Marrow Mesenchymal Stromal Cells Mediates Immunosuppression on Chimeric Antigen Receptor T Cells

Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

PTCY keeps on giving!

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only